Literature DB >> 21191598

33% radius evaluation to assess bone mineral density in prostate cancer patients.

Juan Morote1, Jacques Planas, Maria Carmen Mir, Carles X Raventós, Gloria Encabo, Andreas Doll.   

Abstract

PURPOSE: Dual-energy X-ray absorptiometry (DXA) is the standard method to assess bone mineral density (BMD). The International Society for Clinical Densitometry recommends the measurement of BMD at lumbar spine, total hip and femoral neck, but in certain circumstances the 33% radius may be the recommended area to measure BMD. The aim of this study has been to analyze whether 33% radius should be considered the recommended area to assess BMD in prostate cancer patients.
METHODS: This is a retrospective study where BMD was assessed by DXA at 33% radius, lumbar spine, total hip, and femoral neck (cDXA) in 141 prostate cancer patients. Twenty-eight patients were hormone naïve while 113 were subjected to androgen suppression (AS) during the mean period of 29 months. Osteoporosis was diagnosed when T-score was lower than -2.5 and osteopenia when it ranged between -1 and -2.5.
RESULTS: The osteoporosis rate was 29.8% at 33% radius, 23.4% at femoral neck, 19.9% at lumbar spine, and 12.8% at total hip. The overall osteoporosis rate at cDXA was 29.1%. Osteoporosis was detected in 52.2% at 33% radius and 36.2% at cDXA. Normal BMD was found in 17.7% at 33% radius and 34.8% at cDXA. The 33% radius was the only site where a significant increase in the osteoporosis rate was detected in patients subjected to AS compared to those hormone naïve (33 and 13.8%).
CONCLUSIONS: The 33% radius seems more sensible than the central skeleton areas to detect bone mass loss in patients with prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191598     DOI: 10.1007/s00345-010-0630-7

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

Review 1.  The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry.

Authors:  John A Kanis; Ego Seeman; Olof Johnell; Rene Rizzoli; Pierre Delmas
Journal:  Osteoporos Int       Date:  2005-02-24       Impact factor: 4.507

2.  Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.

Authors:  Jan M Bruder; Jennie Z Ma; Joseph W Basler; Michelle D Welch
Journal:  Urology       Date:  2006-01       Impact factor: 2.649

3.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.

Authors:  J F Maillefert; J Sibilia; F Michel; C Saussine; R M Javier; C Tavernier
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

4.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

5.  Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.

Authors:  Juan Morote; Jacques Planas Morin; Anna Orsola; Jose M Abascal; Carles Salvador; Enrique Trilla; Carles X Raventos; Lluis Cecchini; Gloria Encabo; Jaume Reventos
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

6.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

Authors:  H W Daniell; S R Dunn; D W Ferguson; G Lomas; Z Niazi; P T Stratte
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

7.  Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.

Authors:  Daniella Mittan; Shuko Lee; Elizabeth Miller; Reina C Perez; Joseph W Basler; Jan M Bruder
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

8.  Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism.

Authors:  S L Greenspan; D S Oppenheim; A Klibanski
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

9.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors:  D Marshall; O Johnell; H Wedel
Journal:  BMJ       Date:  1996-05-18

Review 10.  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Authors:  Terrence H Diamond; Celestia S Higano; Matthew R Smith; Theresa A Guise; Frederick R Singer
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

View more
  3 in total

Review 1.  Skeletal complications of ADT: disease burden and treatment options.

Authors:  Jacques Planas Morin; Juan Morote Robles
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

2.  Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.

Authors:  S M H Alibhai; H Z Mohamedali; H Gulamhusein; A H Panju; H Breunis; N Timilshina; N Fleshner; M D Krahn; G Naglie; I F Tannock; G Tomlinson; P Warde; S Duff Canning; A M Cheung
Journal:  Osteoporos Int       Date:  2013-04-06       Impact factor: 4.507

3.  Diffuse osteosclerosis in a patient with prostate cancer.

Authors:  N Ustün; I Ustün; T Ozgür; N Atci; F Aydoğan; A T Sümbül; A D Turhanoğlu
Journal:  Osteoporos Int       Date:  2013-10-18       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.